Streetbeat News

TLSI

TriSalus Life Sciences, Inc.

Industry

Medical - Devices

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

Open

4.30

Mkt cap

129M

Volume

31K

High

4.33

P/E Ratio

0.08

52-wk high

10.42

Low

4.16

Div yield

N/A

52-wk low

3.32

NetEase, Inc. (NASDAQ:NTES) shares fell 4% after reporting worse-than-expected first-quarter revenue. Despite a 7.2% year-on-year revenue growth to $3.72 billion, it missed the analyst consensus estimate of $3.79 billion. However, the company's adjusted EPADS of $1.81 beat the consensus estimate of $1.79. Other stocks moving significantly include Akanda Corp. (NASDAQ:AKAN), OneMedNet Corporation (NASDAQ:ONMD), and Verastem, Inc. (NASDAQ:VSTM).

Portfolio Pulse from Avi Kapoor

May 24, 2024 | 5:57 pm

The article highlights significant intraday movements in health care stocks on Friday. Notable gainers include Innovative Eyewear (LUCY), OneMedNet (ONMD), TransCode Therapeutics (RNAZ), Onconetix (ONCO), Aptorum Group (APM), and Immatics (IMTX). Major losers include Verastem (VSTM), Sensei Biotherapeutics (SNSE), Genelux (GNLX), Exicure (XCUR), TriSalus Life Sciences (TLSI), and HOOKIPA Pharma (HOOK).

Portfolio Pulse from Benzinga Insights

May 24, 2024 | 4:31 pm

U.S. stocks traded higher with the Nasdaq Composite gaining around 1%. Intuit shares fell 8% despite better-than-expected earnings due to weak guidance. Akanda Corp. shares surged 70% after a reverse stock split. Merus N.V. shares rose 37% following a positive abstract publication. Deckers Outdoor Corporation shares increased 13% on strong quarterly results. Verastem, Inc. shares dropped 61% after initiating a rolling NDA submission. TriSalus Life Sciences shares fell 26% following an exchange offer announcement. Genelux Corporation shares declined 45% after pricing a $27.5 million stock offering.

Portfolio Pulse from Avi Kapoor

May 24, 2024 | 4:07 pm

JonesTrading analyst Justin Walsh initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and a price target of $16.